Jiangyin Jinghui Biotechnology Service Co., Ltd.

Geneway Biotech Inc. is an enterprise founded by overseas entrepreneurial and innovative leaders introduced by Wuxi 530 Program. The leaders have many years of experience in the field of biotechnology. The research field is very wide, including research reagents in the field of life sciences (development of DNA automatic sequence determination kits, big-dye reagents). The research and development of diagnostic reagents is based on the established quantitative latex technology platform. The products currently developed are mainly concentrated in special protein detection reagents; using PEG modification technology and HSA fusion protein technology to develop second-generation protein recombinant drugs; using humanized mouse technology to develop therapeutic human antibodies (currently mainly focused on the development of vaccines and tumor therapeutic human antibodies); using unique technology to develop recombinant insulin drugs. The cost of recombinant insulin produced by our intellectual property technology can reach 1/3-1/5 of the production cost of recombinant insulin produced by Novo Nordisk. We are determined to change the situation where foreign companies' recombinant insulin occupies the main domestic market with high-quality and low-priced products, and to enable low-income patients in China and other developing countries to use high-quality recombinant insulin, so as to contribute to human health. In the early stages of the company's development, in addition to the research and development of its main products, it also provided a series of technical services and was the exclusive agent for biological reagents from well-known domestic brand companies.